Business Context and Reporting Period
This Form 8-K is a current report filed by OncoCyte Corporation (trading symbol: OCX) on July 29, 2020. The filing serves to announce the company's financial results for the three and six months ended June 30, 2020. The registrant is incorporated in California and its common stock is listed on the NYSE American.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the press release attached as Exhibit 99.1, which is incorporated by reference but not reproduced in the body of this 8-K document.
Material Changes
No material changes or comparative financial data are detailed in the text of this filing. The document solely references the issuance of a press release regarding the results for the periods ended June 30, 2020.
Guidance, Outlook, and Risks
The filing includes a standard disclaimer regarding forward-looking statements, noting that actual results may differ materially from anticipated results due to various factors. It directs investors to the "Risk Factors" section of the company's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q for a detailed discussion of risks and contingencies. The company disclaims any obligation to update these forward-looking statements.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated July 29, 2020) for specific revenue, net loss, and cash position figures.
- Verify the company's liquidity status and burn rate as detailed in the referenced press release.
- Consult the most recent Form 10-K and 10-Q filings for a comprehensive list of risk factors.
- Confirm the trading status of OCX on the NYSE American following the announcement.